Connect with us

Business

FDA does about-face on review of potential ALS treatment from Amylyx – STAT

The decision to review an experimental treatment for amyotrophic lateral sclerosis based on a single study follows pressure from…

Article feature image
ADVERTISEMENT

The Food and Drug Administration has reversed an internal decision and will now review an experimental treatment for amyotrophic lateral sclerosis — a victory for ALS patients and advocates who have been pressuring regulators to act with more urgency against…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Confusion reigns over vaccine booster rollout | TheHill – The Hill
Chinese cities seize Evergrande presales to block potential misuse of funds – Financial Times
Article feature image
Behave normally, UK transport minister tells Britons queuing for fuel – Reuters